A Phase 1 interventional study of Evogliptin→Evogliptin+Glimepiride→Glimepiride and Glimepiride→Evogliptin→Evogliptin+Glimepiride in Type2 Diabetes, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-18.
Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Health services research
A randomized, open-label, multiple dosing, three treatment, three period, two sequence clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and glimepiride 4 mg after oral administration in healthy male subjects
A randomized, open-label, multiple-dose, three-treatment, three-period, two-sequence, crossover study
Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Evogliptin→Evogliptin+Glimepiride→Glimepiride
Drug: Evogliptin→Evogliptin+Glimepiride→Glimepiride
Glimepiride→Evogliptin→Evogliptin+Glimepiride
Drug: Glimepiride→Evogliptin→Evogliptin+Glimepiride
Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days. Glimepiride : Glimepiride 4mg QD Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD
Also known as: Suganon, Amaryl
After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
Also known as: Suganon, Amaryl
AUCτ,ss for Evogliptin and Glimepiride
area under the concentration-time curve
Time frame: 3 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dong-A ST Co., Ltd.